Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

glaxosmithkline (ireland) limited, dublin array - 14181 salmeterol-xinafoÁt - dávkovaný prášek k inhalaci - 50mcg/dÁv - salmeterol

Evropská unie - čeština - EMA (European Medicines Agency)

dompé biotec s.p.a. - cinakalcet - hypercalcemia; parathyroid neoplasms; hyperparathyroidism - vápníková homeostáza - léčba sekundární hyperparatyreózy (hpt) u pacientů s end-stage renálním onemocněním (esrd) při udržovací dialýze. mimpara může být použit jako součást léčebného režimu včetně fosfáty a/nebo derivátů vitaminu d, jako vhodné (viz bod 5. léčba hyperkalcémie u pacientů:-s karcinomem příštítných tělísek. - primární hpt, pro něž kterých by byla indikována na základě sérové calciumlevels (podle příslušného doporučení pro léčbu), ale u kterých paratyroidektomie není klinicky vhodná nebo je kontraindikována.

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

glaxosmithkline (ireland) limited, dublin array - 12768 flutikason-propionÁt - dávkovaný prášek k inhalaci - 100mcg - flutikason

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

glaxosmithkline (ireland) limited, dublin array - 12768 flutikason-propionÁt - dávkovaný prášek k inhalaci - 250mcg - flutikason

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

glaxosmithkline (ireland) limited, dublin array - 12768 flutikason-propionÁt - dávkovaný prášek k inhalaci - 500mcg - flutikason

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

glaxosmithkline (ireland) limited, dublin array - 14181 salmeterol-xinafoÁt; 12768 flutikason-propionÁt - dávkovaný prášek k inhalaci - 50mcg/100mcg - salmeterol a flutikason

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

glaxosmithkline (ireland) limited, dublin array - 14181 salmeterol-xinafoÁt; 12768 flutikason-propionÁt - dávkovaný prášek k inhalaci - 50mcg/250mcg - salmeterol a flutikason

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

glaxosmithkline (ireland) limited, dublin array - 14181 salmeterol-xinafoÁt; 12768 flutikason-propionÁt - dávkovaný prášek k inhalaci - 50mcg/500mcg - salmeterol a flutikason

Česká republika - čeština - USKVBL (Ústav Pro Státní Kontrolu Veterinárních Biopreparátů A Léčiv)

virbac sa - amitraz - medikovaný obojek - 9g - amidines - psi

Evropská unie - čeština - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vakcíny - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. použití této vakcíny musí být v souladu s oficiálními doporučeními.